MTNB — Matinas BioPharma Holdings Share News
0.000.00%
Last trade - 00:00Brief: Matinas Biopharma Announces Unanimous Dsmb Approval To Progress Into Second Cohort Of Patients In The Enact Study Of Mat2203 For The Treatment Of Cryptococcal Meningitis
Brief: Matinas Biopharma Holdings Announces Positive End Of Phase 2 Meeting With FDA For MAT9001 In Severe Hypertriglyceridemia
Brief: Matinas Biopharma Completes Enrollment Of ENHANCE-IT Study Of MAT9001 Against Vascepa
Brief: Matinas Biopharma Files Prospectus Relates To Offer, Sale From Time To Time Of Shares Of Common Stock Having Gross Sales Price Of Up To $50 Mln
Brief: Matinas Biopharma Reports Q2 Loss Per Share $0.03
Brief: Matinas BioPharma Enters Into At-The-Market Sales Agreement With BTIG
Brief: Matinas Biopharma Resumes Enrollment In The Enhance-It And Enact Clinical Trials
Brief: Matinas Biopharma Reports Q4 Loss Per Share Of $0.04
Brief: Matinas Biopharma Announces Initiation Of Enhance-It Study Of Mat9001 Against Vascepa
Brief: Matinas Biopharma Says On Feb 19, Provided Notice Of Its Termination Of Controlled Equity Offering Sales Agreement
U.S. STOCKS ON THE MOVE-Adobe, General Electric, Blue Apron, Groupon, Fresh Del Monte
U.S. STOCKS ON THE MOVE-Adobe, Wanda Sports, TiVo, Eton Pharma
Matinas BioPharma: Rises as fungal meningitis therapy gets approval for trial
Brief: Matinas BioPharma Announces DSMB Approval To Commence Part 2 Of Enact Study Of MAT2203 For Treatment Of Cryptococcal Meningitis
Brief: Matinas Biopharma Announces Pricing Of Public Offering Of Common Stock
Matinas BioPharma drops on deep-discounted stock deal
Brief: Matinas Biopharma Announces Proposed Public Offering Of Common Stock
Matinas BioPharma falls on stock offering launch
U.S. STOCKS ON THE MOVE-Uber, Dick's Sporting, Tencent, Schlumberger